← Back to Search

Other

DC-806 for Plaque Psoriasis (Illuminate Trial)

Phase 2
Waitlist Available
Research Sponsored by DICE Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 20 weeks
Awards & highlights

Illuminate Trial Summary

This trial will look at the effectiveness and safety of a new medication to treat plaque psoriasis. It will last 12 weeks and involve multiple doses of the drug.

Who is the study for?
Adults aged 18-70 with moderate to severe plaque psoriasis, who have had it for at least 6 months and are candidates for phototherapy or systemic therapy. They must have a BMI of 18-40 kg/m2 and agree to use effective contraception. Exclusions include certain abnormal lab values, recent flares or infections, history of significant mental health issues, strong drug interactions, heart abnormalities, chronic infections like HIV/hepatitis/TB, cancer in the last 5 years (except some skin cancers), or no response to specific psoriasis treatments.Check my eligibility
What is being tested?
The trial is testing DC-806's effectiveness and safety compared to a placebo over a period of 12 weeks. Participants will be randomly assigned to receive either multiple oral doses of DC-806 or a placebo in double-blind fashion (neither participants nor researchers know who receives which treatment). The study also looks into how the body processes the drug.See study design
What are the potential side effects?
While not specified here, common side effects for new psoriasis medications can include symptoms like nausea, diarrhea, headache, fatigue and potential risks for infection due to immune system impact. Specific side effects related to DC-806 would be detailed based on previous research phases.

Illuminate Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~20 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 20 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of TEAEs leading to discontinuation
Incidence of serious adverse events (SAEs)
Incidence of treatment-emergent adverse events (TEAEs)
+1 more

Illuminate Trial Design

5Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment Group 4: DC-806 Dose DExperimental Treatment1 Intervention
Group II: Treatment Group 3: DC-806 Dose CExperimental Treatment1 Intervention
Group III: Treatment Group 2: DC-806 Dose BExperimental Treatment1 Intervention
Group IV: Treatment Group 1: DC-806 Dose AExperimental Treatment1 Intervention
Group V: Treatment Group 5: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DC-806
2023
Completed Phase 1
~70

Find a Location

Who is running the clinical trial?

DICE Therapeutics, Inc.Lead Sponsor
2 Previous Clinical Trials
41 Total Patients Enrolled
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyLead Sponsor
5 Previous Clinical Trials
149 Total Patients Enrolled

Media Library

DC-806 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05896527 — Phase 2
Plaque Psoriasis Research Study Groups: Treatment Group 3: DC-806 Dose C, Treatment Group 5: Placebo, Treatment Group 1: DC-806 Dose A, Treatment Group 2: DC-806 Dose B, Treatment Group 4: DC-806 Dose D
Plaque Psoriasis Clinical Trial 2023: DC-806 Highlights & Side Effects. Trial Name: NCT05896527 — Phase 2
DC-806 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05896527 — Phase 2
Plaque Psoriasis Patient Testimony for trial: Trial Name: NCT05896527 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who would be a fitting participant in this clinical trial?

"This clinical trial requires that individuals who have plaque psoriasis and are between 18-70 years old can apply for the study. Approximately 225 participants will be accepted."

Answered by AI

What safety protocols apply to subjects receiving DC-806 Dose A in Treatment Group 1?

"As Treatment Group 1: DC-806 Dose A is only in Phase 2 of its clinical studies, there is evidence to suggest safety but not efficacy yet. Thus, our team at Power gave the medication a tentative score of 2 on their scale from 1 to 3."

Answered by AI

Are there any new openings in this investigation for participants?

"Affirmative, the trial is actively recruiting as indicated on clinicaltrials.gov. It was posted in May 11th 2023 and has been updated until 31st of that same month. This research project needs to enrol 225 people across 60 locations."

Answered by AI

How many clinical sites are currently conducting this research?

"Participants are able to enrol in this medical trial at 60 different sites. Notably, some of these locations include Fountain Valley, San Francisco and Santa Monica amongst other places. To reduce travel burden it is essential individuals select the centre closest to them for participation purposes."

Answered by AI

What is the upper limit of participants taking part in this clinical experiment?

"Affirmative. Data displayed on clinicaltrials.gov affirms that this experiment is actively enrolling participants at 60 sites across the US, with an initial posting date of May 11th 2023 and most recent update occurring on May 31st 2023. The trial requires 225 patients in total to complete their research objectives."

Answered by AI

Does this trial accommodate applicants aged thirty or above?

"This trial is open to participants aged between 18 and 70. However, there are 25 studies available for minors and 138 dedicated towards elderly patients."

Answered by AI

Who else is applying?

What state do they live in?
Kentucky
What site did they apply to?
DICE Therapeutics Study Site
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
1

Why did patients apply to this trial?

I would love to finally feel free from my psoriasis.
PatientReceived 2+ prior treatments
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis
2023. "A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05896527.
All > Psoriasis > Plaque Psoriasis
~119 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top